Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9543MR)

This product GTTS-WQ9543MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 608
UniProt ID Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9543MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6834MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ14301MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RG-7221
GTTS-WQ11141MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MDX-1103
GTTS-WQ6042MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ7438MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ666MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 8H9
GTTS-WQ13630MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA R4930
GTTS-WQ9472MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IPH-5401
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW